The FDA does not review compounded drugs for safety, effectiveness, or quality; compounded medications are not FDA-approved
Expert discusses identifying and managing nutrient deficiencies or eating habits that can contribute to mental health conditions including depression and anxiety
Odds of infection, venous thromboembolism, renal complications increased for patients with overweight, obesity.
Wegovy is a glucagon-like peptide-1 receptor agonist.
Tirzepatide is a once-weekly, dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.
Researchers analyzed the relationship between dietary choline and betaine intake and serum lipids, blood pressure, and glycemic markers among individuals with obesity.
Dr Zhaoping Li discusses 2 ongoing studies investigating the use of precision nutrition for personalized weight loss plans.
The findings contribute to the understanding of neurological factors driving the sex-specific pathophysiology of obesity.
The researchers found that nearly 3 in 10 Americans became more worried about having obesity, with greater concern seen among Black and Hispanic Americans.
Karli Burridge’s interest in obesity medicine began shortly after earning her PA degree and led her to cofound PAs in Obesity Medicine and Gaining Health, which help clinicians start obesity treatment programs.
Survey respondents are cautious about the long-term effects of using antiobesity medications and bariatric surgery as recommended in the AAP childhood obesity guideline.
Novo Nordisk plans to file for regulatory approval of the 25mg and 50mg dosage strengths in 2023.
Obesity experts discuss how semaglutide and tirzepatide are changing the treatment landscape and challenges affecting access including drug shortages, inappropriate prescribing, insurance coverage, and cost.
A study was conducted to determine real-world outcomes for patients taking liraglutide, lorcaserin, or orlistat therapy for obesity.
Gina A. Friel, DNP, RN, CRNP-PC discusses her interest in patients with overweight and obesity, food insecurity, and her efforts to improve health and wellbeing, diet quality, and social equity.
Those with type 1 diabetes are least likely to increase physical activity, reduce caloric intake to manage overweight or obesity.
Obesity experts discuss the cost of newer obesity medications (eg, GLP-1 agonists) and access issues, including Ozempic shortages.
The company expects ‘pent-up demand’ for the Wegovy (semaglutide) to subside within the next few months
Two more medical societies have come out in support of the AAP’s updated clinical guidelines for obesity treatment in children and adolescents and one opposes it.
One-year moderate, vigorous exercise programs tied to reduction in 10-year risk for diabetes among adults with obesity.